ALSO NOTED: J&J recalls children's Tylenol; PharmaFrontiers releases Phase I/II data; XenoPort cuts IPO price; and much mor

> Johnson & Johnson says it is recalling children's Tylenol out of concern that its packaging could lead to overdosing. Story

> PharmaFrontiers has released positive interim data from two Phase I/II trials of multiple sclerosis. Release

> Santa Clara, California-based XenoPort cut the share price of its IPO to $10.50, down from an initial range of $14 to $16 per share. XenoPort is focused on improving the efficacy of existing drugs. Story

> BioDelivery Systems International has rounded up $2.5 million in new financing. Release

> The UK's TranXenogen says that the buyer for its building has pulled out of negotiations. Story

> Vancouver-based InNexus Biotechnology has announced it has expanded its intellectual property portfolio. Release 

And Finally... For the first time, the CDC has studied an outbreak of obesity as it would track an infectious disease. Story

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.